SG10201607346XA - Angiopoietin-like 4 and its use in modulating cell leakiness - Google Patents

Angiopoietin-like 4 and its use in modulating cell leakiness

Info

Publication number
SG10201607346XA
SG10201607346XA SG10201607346XA SG10201607346XA SG10201607346XA SG 10201607346X A SG10201607346X A SG 10201607346XA SG 10201607346X A SG10201607346X A SG 10201607346XA SG 10201607346X A SG10201607346X A SG 10201607346XA SG 10201607346X A SG10201607346X A SG 10201607346XA
Authority
SG
Singapore
Prior art keywords
angiopoietin
modulating cell
leakiness
cell leakiness
modulating
Prior art date
Application number
SG10201607346XA
Inventor
Nguan Soon Tan
Original Assignee
Univ Nanyang Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nanyang Tech filed Critical Univ Nanyang Tech
Publication of SG10201607346XA publication Critical patent/SG10201607346XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
SG10201607346XA 2011-08-08 2012-08-08 Angiopoietin-like 4 and its use in modulating cell leakiness SG10201607346XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161521031P 2011-08-08 2011-08-08

Publications (1)

Publication Number Publication Date
SG10201607346XA true SG10201607346XA (en) 2016-10-28

Family

ID=47668720

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201607346XA SG10201607346XA (en) 2011-08-08 2012-08-08 Angiopoietin-like 4 and its use in modulating cell leakiness
SG10202101995WA SG10202101995WA (en) 2011-08-08 2012-08-08 Angiopoietin-like 4 and its use in modulating cell leakiness

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202101995WA SG10202101995WA (en) 2011-08-08 2012-08-08 Angiopoietin-like 4 and its use in modulating cell leakiness

Country Status (5)

Country Link
US (2) US20140242084A1 (en)
EP (2) EP3399316A1 (en)
CN (2) CN107536847A (en)
SG (2) SG10201607346XA (en)
WO (1) WO2013022406A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201406420XA (en) * 2009-10-14 2014-11-27 Univ Nanyang Tech Antiproliferative agent
EP2885319B1 (en) * 2012-08-14 2019-10-09 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
WO2015157655A2 (en) * 2014-04-10 2015-10-15 University Of Tennessee Research Foundation Method for predicting response to vegf targeted therapeutics
MX2017001746A (en) * 2014-08-07 2017-04-27 Novartis Ag Angiopoietin-like 4 antibodies and methods of use.
CA3103560C (en) 2014-09-26 2023-01-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN106955349A (en) * 2016-01-11 2017-07-18 石家庄以岭药业股份有限公司 Application of the PP1158 4 in protection endothelial barrier function
CN106822873B (en) * 2017-02-24 2020-07-03 山东大学 Use of mature form IL-37 in the preparation of drugs for inhibiting tumor metastasis
AU2020399633A1 (en) * 2019-12-09 2022-07-07 Empirico Inc. Oligonucleotides for treatment of Angiopoietin like 4 (ANGPTL4) related diseases
CN111549000B (en) * 2020-06-18 2022-07-29 中国医学科学院整形外科医院 Recombinant adipose-derived stem cell for over-expression of Hpgds, preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2380411C2 (en) * 2004-07-20 2010-01-27 Дженентек, Инк. Method for inhibition of hepatocyte proliferation, method for inhibition of hepatocyte cell adhesion and method for inhibition of biological activity angptl4 in hepatocytes or hepatocyte precursors
EP2172482A1 (en) * 2004-07-20 2010-04-07 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
JP5366406B2 (en) * 2005-01-07 2013-12-11 レキシコン ファーマシューティカルズ インコーポレーテッド Monoclonal antibody against Angiopoietin-like protein 4 (ANGPTL4)
SG10201406420XA (en) * 2009-10-14 2014-11-27 Univ Nanyang Tech Antiproliferative agent

Also Published As

Publication number Publication date
EP2742361A1 (en) 2014-06-18
US20140242084A1 (en) 2014-08-28
CN103782177A (en) 2014-05-07
WO2013022406A1 (en) 2013-02-14
EP3399316A1 (en) 2018-11-07
CN107536847A (en) 2018-01-05
US20180319878A1 (en) 2018-11-08
CN103782177B (en) 2017-10-03
SG10202101995WA (en) 2021-04-29
EP2742361A4 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
SG10202101995WA (en) Angiopoietin-like 4 and its use in modulating cell leakiness
IL221511A (en) Bisaryl-linked aryltriazolones and their use
IL227678B (en) Triterpenoids modified in positions 3 and 17
HK1184488A1 (en) Human facilitating cells and uses thereof
ZA201208173B (en) Peptices and their use
IL225713A0 (en) Cytopheretic cartridge and use thereof
IL239588A0 (en) Conserving battery and data usage
PL2916855T3 (en) Collagen hydrolyzate and use thereof
ZA201304235B (en) Oprf/i agents and their use in hospitalized and other patients
PT2521445T (en) Formulation and use thereof
PL2648715T3 (en) Carnosine-hyaluronic acid mixtures and their use
EP2737469A4 (en) Educational application generator and educational reader
HK1211419A1 (en) Improvements in water storage devices and apparatuses therefor
GB201212724D0 (en) Azaphthalocyanines and their use in ink-jet printing
ZA201206667B (en) Improvements in and relating to implements
GB201004417D0 (en) Azaphthalocyanines and their use in ink-jet printing
GB201212468D0 (en) Using linguistically-aware variables in computer-generated text
GB201223301D0 (en) Improvements in or relating to storage and display
GB201223310D0 (en) Improvements in or relating to storage and display
GB201223305D0 (en) Improvements in or relating to storage and display
GB201223300D0 (en) Improvements in or relating to storage and display
GB201201847D0 (en) Improvements in or relating to storage and display
GB201201848D0 (en) Improvements in or relating to storage and display
IL230701A0 (en) Educational application generator and educational reader
GB201021550D0 (en) Improvements in or relating to storage and display